Company Overview and News

112
Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge - Bloomberg

2018-06-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
RXDX RHHVF LOXO RHHBY FMI ILMN RHHBF

104
FMI / Foundation Medicine, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-19 fintel.io
Foundation Medicine, Inc. (NASDAQ:FMI) has 157 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,828,278 shares. Largest shareholders include Gilder Gagnon Howe & Co Llc, BlackRock Inc., Vanguard Group Inc, BlackRock Fund Advisors, Chevy Chase Trust Holdings, Inc., Discovery Group I, LLC, State Street Corp, Oppenheimer & Co Inc, Lord, Abbett & Co.
STT PRTO STT.PRC STT.PRE STT.PRD STT.PRG GALPW RHHBF BLK RHHVF RHHBY FMI GALE GALEW

18
Roche to pay US$2.4 billion to buy rest of Foundation Medicine

2018-06-19 channelnewsasia
ZURICH: Roche Holding AG has agreed to pay US$137 per share to buy the rest of Foundation Medicine (FMI), valuing the U.S. genomic profiling group at US$5.3 billion, the partners said on Tuesday.
RHHVF RHHBY FMI RHHBF

18
Roche to pay $2.4 bln to buy rest of Foundation Medicine

2018-06-19 reuters
ZURICH (Reuters) - Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), valuing the U.S. genomic profiling group at $5.3 billion, the partners said on Tuesday.
RHHVF RHHBY FMI RHHBF

132
Another Alzheimer’s drug fails as Lilly, AstraZeneca halt tests

2018-06-12 sfgate
Eli Lilly and AstraZeneca ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness.
RHHVF BIIB RHHBY ABBV ABBV RHHBF

167
Another Alzheimer’s drug fails as Lilly, Astra halt tests

2018-06-12 malaymail
PARIS, June 12 — Eli Lilly & Co and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness.
RHHVF BIIB AZN RHHBY ABBV ABBV RHHBF

15
Takeda shareholder group aims to block US$62b Shire deal

2018-06-11 malaymail
TOKYO, June 11 — A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the US$62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters today.
RHHVF RHHBY RHHBF

15
Takeda shareholder group aims to block US$62 billion Shire deal

2018-06-11 channelnewsasia
A group of Takeda Pharmaceutical Co Ltd shareholders is building support to block the US$62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters on Monday.
RHHVF RHHBY RHHBF

15
Blockbuster Drugs? How About Doing More With What We've Got - Bloomberg

2018-06-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
RHHVF RHHBY RHHBF

14
Roche Holding ADR (RHHBY) Presents At Deutsche Bank Securities Inc. DbAccess Berlin Conference - Slideshow

2018-06-06 seekingalpha
The following slide deck was published by Roche Holding Ltd ADR in conjunction with this event.
RHHBY RHHBF

30
Research Yields Progress Against Lung Cancer - WSJ

2018-06-05 wsj
CHICAGO—Cancer researchers presented more evidence of advances against one of the deadliest and most common forms of the disease—lung cancer—at a major medical meeting here.
NKTR RHHVF LOXO RHHBY RHHBF

71
Two Roche Cancer Drugs Get Disappointing Results

2018-06-04 biospace
Bad news for Roche Holding AG. Two of its cancer drugs, Tecentriq and taselisib, have been shown to provide only modest protection from disease progression. The findings were released at the American Society of Clinical Oncology annual meeting in Chicago on Saturday.
RHHVF CELGZ CELG RHHBY RHHBF

31
This Fungus Could Help Cure Cancer - Bloomberg

2018-06-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ RHHVF RHHBY 500680 PFE PFIZER RHHBF

72
Roche drugs show limited benefit in lung, breast cancer trials - Channel NewsAsia

2018-06-02 channelnewsasia
In a disappointment for Roche Holding AG, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials presented on Saturday.
RHHVF CELGZ CELG RHHBY TRI RHHBF

72
Roche drugs show limited benefit in lung, breast cancer trials

2018-06-02 reuters
CHICAGO, June 2 (Reuters) - In a disappointment for Roche Holding AG, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials presented on Saturday.
RHHVF CELGZ CELG RHHBY RHHBF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 771195104